Cell-Based Ophthalmic Therapies Market Report 2026

Cell-Based Ophthalmic Therapies Market Overview

• Cell-Based Ophthalmic Therapies market size has reached to $1.48 billion in 2025 • Expected to grow to $3.78 billion in 2030 at a compound annual growth rate (CAGR) of 20.5% • Growth Driver: Increasing Prevalence Of Ophthalmic Disorders Fueling The Growth Of The Market Due To Rising Vision Impairment Burden • Market Trend: Breakthrough Allogeneic cell therapy Advances Treatment For Corneal Endothelial Diseases • North America was the largest region in 2025.

What Is Covered Under Cell-Based Ophthalmic Therapies Market?

Cell-based ophthalmic therapies are treatments for eye diseases that use living cells to repair, replace, or protect damaged ocular tissues. They target eye conditions that are difficult to treat with conventional methods by encouraging tissue repair and improving eye function. They provide promising, lasting solutions for vision impairment and enhance patients’ eyesight and overall quality of life through innovative regenerative medicine. The main types of cell-based ophthalmic therapies are stem cell therapy, gene therapy, and tissue engineering. Stem cell therapy is a medical treatment that uses stem cells to repair, replace, or regenerate damaged or diseased tissues and organs in the body. It is used in various applications such as retinal disorders, corneal disorders, glaucoma, and others, and also used by various end users such as hospitals, ophthalmic clinics, research institutes, and others.

What Is The Cell-Based Ophthalmic Therapies Market Growth Forecast?

The cell-based ophthalmic therapies market size is expected to see exponential growth in the next few years. It will grow to $3.78 billion in 2030 at a compound annual growth rate (CAGR) of 20.5%. The growth in the forecast period can be attributed to advancements in stem cell and gene editing technologies, increasing investment in regenerative ophthalmology, rising regulatory approvals for cell-based therapies, growing demand for long-term vision restoration solutions, expansion of specialized ophthalmic treatment centers. Major trends in the forecast period include increasing adoption of stem cell and gene therapies for vision restoration, rising focus on regenerative treatments for retinal and corneal disorders, growth in clinical trials for cell-based ophthalmic therapies, expansion of personalized and precision ophthalmic treatments, improved long-term outcomes compared to conventional ophthalmic therapies.

Global Cell-Based Ophthalmic Therapies Market Segmentation

1) By Therapy Type: Stem Cell Therapy, Gene Therapy, Tissue Engineering 2) By Application: Retinal Disorders, Corneal Disorders, Glaucoma, Other Applications 3) By End-User: Hospitals, Ophthalmic Clinics, Research Institutes, Other End-Users Subsegments: 1) By Stem Cell Therapy: Embryonic Stem Cell Therapy, Mesenchymal Stem Cell Therapy, Induced Pluripotent Stem Cell Therapy, Retinal Pigment Epithelium Cell Therapy, Limbal Stem Cell Therapy 2) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector Based Gene Therapy, In-Vivo Gene Therapy, Ex-Vivo Gene Therapy, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Therapy 3) By Tissue Engineering: Bioengineered Corneal Tissue, Amniotic Membrane Transplantation, Hydrogel-Based Scaffolds, Synthetic Polymer Scaffolds, Decellularized Tissue Constructs

What Is The Driver Of The Cell-Based Ophthalmic Therapies Market?

The increasing prevalence of ophthalmic disorders is expected to propel the growth of the cell-based ophthalmic therapies market going forward. Ophthalmic disorders refer to diseases or conditions impacting the eyes, that create vision problems or damage to eye health. Ophthalmic disorders are on the rise as the aging population faces a greater risk of age-related eye diseases, resulting to vision impairment with longer life expectancy. Cell-based ophthalmic therapies repair or replace damaged retinal and eye cells to restore vision and prevent further damage while promoting regeneration and enhancing overall eye function. For instance, in August 2024, according to the Welsh Government, a UK-based government agency, ophthalmology departments in Wales recorded over 35,000 admissions in 2023-24, marking a 5.8% increase from 2022-2023. Therefore, the increasing prevalence of ophthalmic disorders is driving the growth of the cell-based ophthalmic therapies industry.

Key Players In The Global Cell-Based Ophthalmic Therapies Market

Major companies operating in the cell-based ophthalmic therapies market are F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Astellas Pharma Inc., Sumitomo Pharma Co. Ltd., Healios K.K., Lineage Cell Therapeutics, Pandorum Technologies Pvt. Ltd., Neurotech Pharmaceuticals Inc., Coave Therapeutics SAS, jCyte Inc., Eyestem Research Pvt. Ltd., Opsis Therapeutics, Regenerative Patch Technologies LLC, Emmetrope Ophthalmics LLC, GenSight Biologics S.A., MEDIPOST Co. Ltd., Riken, Luxa Biotechnology Inc.

Global Cell-Based Ophthalmic Therapies Market Trends and Insights

Major companies operating in the cell-based ophthalmic therapies market are focusing on developing advanced treatments, such as allogeneic cell therapy, to address unmet needs in treating corneal endothelial diseases. Allogeneic cell therapy refers to a treatment that uses stem cells or other cells donated by a genetically different individual of the same species to repair or replace damaged tissues or treat diseases. For instance, in September 2024, Aurion Biotech, Inc., a US-based clinical-stage biotechnology company, announced the commercial launch of Vyznova (neltependocel) in Japan. It is designed for the treatment of bullous keratopathy, a debilitating condition of the corneal endothelium. Vyznova is believed to be the first approved allogeneic cell therapy specifically targeting corneal endothelial disease, having secured both regulatory and reimbursement approvals in Japan.

What Are Latest Mergers And Acquisitions In The Cell-Based Ophthalmic Therapies Market?

In March 2025, Alcon Inc., a Switzerland-based eye care company, acquired a majority interest in Aurion Biotech, Inc. for an undisclosed amount. With this acquisition, Alcon aims to advance Aurion Biotech’s clinical-stage allogeneic cell therapy, AURN001, into Phase 3 development for treating corneal edema secondary to corneal endothelial disease, while expanding its ophthalmic pharmaceutical portfolio. Aurion Biotech Inc. is a US-based clinical-stage company developing advanced cell therapies to treat eye diseases.

Regional Insights

North America was the largest region in the cell-based ophthalmic therapies market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Cell-Based Ophthalmic Therapies Market?

The cell-based ophthalmic therapies market consists of revenues earned by entities by providing services such as clinical trial services, ocular cell therapy consultation, post-therapy monitoring and support, research and development services, and regulatory and compliance services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell-based ophthalmic therapies market also includes sales of neural progenitor cell injections, bioengineered retinal pigment epithelium scaffolds, autologous mesenchymal stem cell grafts, and ex-vivo expanded conjunctival epithelial cell sheets. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cell-Based Ophthalmic Therapies Market Report 2026?

The cell-based ophthalmic therapies market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cell-based ophthalmic therapies industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.